Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.80 |
| ▸ | LAP3 | P28838 | 1/20 | 0.80 |
| ▸ | PPARA | Q07869 | 4/20 | 0.60 |
| ▸ | PPARG | P37231 | 4/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.56 |
| ▸ | PPARD | Q03181 | 1/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | REN | P00797 | 1/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8525732 | 0.89 | LTA4H (1.00) | LTA4HLAP3PPARAPPARGFFAR1 | |
| SCHEMBL220808 | 0.89 | LTA4H (1.00) | LTA4HLAP3PPARAPPARGFFAR1 | |
| SCHEMBL220809 | 0.89 | LTA4H (1.00) | LTA4HLAP3PPARAPPARGFFAR1 | |
| SCHEMBL19143629 | 0.85 | LTA4H (0.70) | LTA4HLAP3PPARAPPARGFFAR1 | |
| SCHEMBL2029167 | 0.84 | ALPI (0.62) | LTA4HLAP3 | |
| SCHEMBL7698421 | 0.84 | ALPI (0.62) | LTA4HLAP3 | |
| SCHEMBL3841332 | 0.84 | ALPI (0.62) | LTA4HLAP3 | |
| SCHEMBL7436847 | 0.84 | ALPI (0.62) | LTA4HLAP3 | |
| SCHEMBL7415433 | 0.84 | ALPI (0.62) | LTA4HLAP3 | |
| SCHEMBL650855 | 0.84 | ALPI (0.62) | LTA4HLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| US-4240975-A | USED AS ENZYME INHIBITOR, ANTIFERTILITY AGENT, AND ENHANCES THE ANTITUMOR EFFECT OF BLEOMYCIN | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1980-12-23 | — | — | US | disclosed |
| US-4189604-A | PEPTIDASE ENZYME INHIBITORS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | LTA4H 2639/4885LAP3 4399/4885PPARA 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.